Barrett & Company’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
AIM
FWIA
DLA
ETC
Barrett & Company's BMY Position: Q2 2026 in Review
Barrett & Company increased its Bristol-Myers Squibb (BMY) stake by 1.9% in Q2 2026, buying an estimated $6.03K and bringing the position to 5,493 shares worth $317K. The position accounts for 0.09% of the portfolio, ranked #121.
Barrett & Company first reported a position in BMY in Q3 2022 and has held it in 16 quarters since. The position peaked at $988K in Q4 2022. 863 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Barrett & Company held 5,493 shares of Bristol-Myers Squibb worth $317K as of Q2 2026.
- Barrett & Company bought 105 Bristol-Myers Squibb shares in Q2 2026, an estimated $6.03K.
- Bristol-Myers Squibb made up 0.09% of Barrett & Company's portfolio in Q2 2026, its #121 holding.
- Barrett & Company first reported a position in Bristol-Myers Squibb in Q3 2022 and has held it in 16 quarters since.
- Barrett & Company's Bristol-Myers Squibb position peaked at $988K in Q4 2022.
- 863 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Barrett & Company's 13F filing for Q2 2026, filed 24 Jul 2026.